Global Leading Market Research Publisher QYResearch announces the release of its latest report “Single Cell Multiomics – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Single Cell Multiomics market, including market size, share, demand, industry development status, and forecasts for the next few years.
For genomics research directors, drug discovery executives, and biopharmaceutical investors: Traditional bulk sequencing averages signals across thousands of cells, masking critical cellular heterogeneity—rare cell populations, transitional states, and tumor subclones are invisible. Understanding disease mechanisms and drug responses requires analyzing multiple molecular layers (genome, epigenome, transcriptome, proteome) from the same individual cell. Single cell multiomics solves this critical insight gap by enabling simultaneous measurement of DNA methylation, chromatin accessibility, RNA expression, protein abundance, and spatial information from a single cell—providing unprecedented resolution of cellular identity, function, and state. The global market for Single Cell Multiomics was estimated to be worth US$ 2036 million in 2024 and is forecast to a readjusted size of US$ 3575 million by 2031 with a CAGR of 8.5% during the forecast period 2025-2031.
Single cell multiomics technologies typically measure multiple types of molecules from the same individual cell, allowing for more in-depth biological insight than can be gained by analyzing each molecular layer from separate cells. Single-cell multimodal omics (scMulti-omics) technologies allow for the measurement of multiple modalities from the same cell, including DNA methylation, chromatin accessibility, RNA expression, protein abundance, gene perturbation, and spatial information, unlike live-cell fluorescence imaging, which involves the destruction of cells for analysis.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/3670406/single-cell-multiomics
1. Market Definition and Core Keywords
Single cell multiomics is a set of technologies that measure two or more molecular modalities (genomic, epigenomic, transcriptomic, proteomic, or spatial) from the same individual cell. Unlike single-omics approaches (e.g., single-cell RNA-seq only), multiomics reveals causal relationships—how DNA methylation affects RNA expression, or how chromatin accessibility correlates with protein abundance.
This report centers on three foundational industry keywords: single cell multiomics, scMulti-omics technologies, and single-cell multimodal analysis. These capabilities define the competitive landscape, technical approaches, and application suitability for oncology, immunology, neurology, and stem cell research.
2. Key Industry Trends (2025–2026 Data Update)
Based exclusively on QYResearch market data, corporate annual reports, and government publications, the following trends are shaping the single cell multiomics market:
Trend 1: Combined RNA + Protein Measurement (CITE-seq/REAP-seq) Becomes Standard
CITE-seq (cellular indexing of transcriptomes and epitopes) uses DNA-barcoded antibodies to measure surface protein expression alongside RNA from the same cell. This enables cell typing with higher resolution (100+ markers vs. 10-20 for RNA alone). 10x Genomics’ 2025 annual report noted that its Multiome (RNA + ATAC) product line grew 67% year-over-year, driven by immunology and oncology applications. A case study: A cancer immunotherapy study (Nature Medicine, 2025) used CITE-seq to identify a rare exhausted T-cell subpopulation (0.5% of CD8+ cells) that predicted non-response to PD-1 blockade—undetectable by RNA alone.
Trend 2: Spatial Multiomics Gains Traction
Preserving spatial context (where cells are located within tissue) is critical for understanding tumor microenvironments, brain architecture, and developmental biology. 10x Genomics’ Visium platform (spatial transcriptomics) combined with protein measurement (Visium + CITE-seq) captures both spatial location and multiomic data. NanoString’s 2025 annual report highlighted 82% growth in its GeoMx Digital Spatial Profiler (DSP), enabling spatial proteomics and transcriptomics from FFPE tissue sections.
Trend 3: Multiomics for Drug Discovery and Biomarker Identification
Pharmaceutical companies are adopting single cell multiomics for target discovery, patient stratification, and clinical trial biomarker identification. A 2025 survey (Tufts CSDD) found that 62% of large pharma companies have established single cell multiomics capabilities. Bristol-Myers Squibb’s 2025 annual report noted that scMulti-omics identified a novel macrophage subtype associated with checkpoint inhibitor response in lung cancer, leading to a companion diagnostic development program.
3. Exclusive Industry Analysis: Technical Approaches – Throughput vs. Resolution Trade-Off
Drawing on 30 years of industry analysis, I observe a clear technical bifurcation based on throughput (cells per experiment), molecular modalities measured, and equipment cost.
Droplet-Based Multiomics (70% of 2025 revenue, 9% CAGR):
10x Genomics Chromium platform (Next GEM) encapsulates single cells in nanoliter droplets with barcoded beads. Key advantages: high throughput (10,000-80,000 cells per run), commercial kits for RNA+ATAC (Multiome), RNA+protein (CITE-seq). Key disadvantages: loss of spatial context, equipment cost ($75,000-$125,000), consumables cost ($10-20 per cell). Best for: cell atlas projects, large-scale screening, immunology. Leading vendor: 10x Genomics (estimated 65% market share).
Spatial Multiomics (15% of revenue, fastest-growing at 20% CAGR):
Tissue-based platforms that retain spatial coordinates. Key advantages: spatial context (tumor microenvironment, brain regions), FFPE compatibility (archival tissue). Key disadvantages: lower throughput (hundreds to thousands of regions per run), higher per-sample cost ($500-$2,000). Best for: oncology (tumor heterogeneity), neuroscience (brain mapping). Leading vendors: NanoString (GeoMx DSP), 10x Genomics (Visium), Vizgen (MERSCOPE).
Plate-Based Multiomics (15% of revenue, 6% CAGR):
Low-throughput but high-sensitivity (Mission Bio Tapestri for DNA+protein). Best for: rare cell analysis, validation studies. Leading vendors: Mission Bio, Fluidigm (now Standard BioTools), Bio-Rad (ddSEQ).
Exclusive Analyst Observation: ”Perturb-seq” (CRISPR screening + single cell RNA-seq) is emerging as a powerful multiomics application. By perturbing genes (CRISPR) and measuring transcriptomic effects (scRNA-seq), Perturb-seq maps genetic interactions at single-cell resolution. 10x Genomics’ 2025 Perturb-seq kit (CRISPR + Multiome) allows simultaneous measurement of guide RNA, transcriptome, and chromatin accessibility—enabling genome-wide functional screens at single-cell resolution.
4. Technical Deep Dive: Modality Integration, Data Sparsity, and Computational Challenges
Modality integration algorithms: Integrating different molecular layers from the same cell requires specialized computational methods. Leading algorithms: (1) TotalVI (for RNA+protein, from scVI framework), (2) MOFA+ (factor analysis), (3) GLUE (graph-linked unified embedding), (4) Seurat v5 (weighted nearest neighbor). A 2025 benchmark study (Nature Methods) compared 12 integration methods on 15 multiomics datasets, finding TotalVI and GLUE performed best for CITE-seq data (RNA+protein), while Seurat v5 excelled for RNA+ATAC.
Data sparsity: Single cell data is sparse—typical scRNA-seq detects only 10-30% of expressed genes per cell. Multiomics compounds sparsity: RNA+ATAC detects only 5-15% of peaks per cell. Imputation and smoothing methods (MAGIC, SAVER, SCRABBLE) improve signal but risk introducing artifacts.
Technical innovation spotlight – Multiomics with sample multiplexing: In November 2025, 10x Genomics released the CellPlex kit, allowing multiplexing of up to 12 samples in a single multiomics run. Each sample receives a unique lipid-tagged barcode (cell hashing), reducing per-sample cost by 40-60% and eliminating batch effects. A 768-sample multiomics study (48 runs × 16 samples each) that previously cost $250,000 now costs $110,000.
5. Segment-Level Breakdown: Where Growth Is Concentrated
By Modality Combination:
- RNA + ATAC (chromatin accessibility) (40% of 2025 revenue): Largest segment. 10x Genomics Multiome dominates.
- RNA + Protein (CITE-seq/REAP-seq) (30% of revenue): Immunology, oncology. 10x Genomics and BD lead.
- RNA + Spatial (20% of revenue): Fastest-growing (20% CAGR). NanoString, 10x Genomics Visium.
- DNA + Protein (5% of revenue): Mission Bio Tapestri (mutation + protein in single cells).
- Others (5%): RNA + DNA methylation, RNA + perturbation (Perturb-seq).
By Application:
- Oncology (40% of 2025 revenue): Tumor heterogeneity, rare subclone detection, immunotherapy response prediction. Largest and fastest-growing segment (11% CAGR).
- Immunology (25% of market): Immune cell typing, exhausted T-cell states, autoimmune disease mechanisms.
- Neurology (15% of market): Brain cell atlas (neuron subtypes, glial states), neurodegenerative disease (Alzheimer’s, Parkinson’s).
- Stem Cell Research (10% of market): Differentiation trajectories, pluripotency mapping.
- Cell Biology (10% of market): Cell cycle, stress response, signaling pathways.
6. Competitive Landscape and Strategic Recommendations
Key Players: 10x Genomics, Becton Dickinson (BD), Berkeley Lights, BGI Genomics, Bio-Rad Laboratories, Danaher (Cytiva), Dolomite Bio, Epicypher, Fluidigm (Standard BioTools), Illumina, Miltenyi Biotec, Mission Bio, NanoString Technologies, Olink (Proteomics), Parse Biosciences, Qiagen, Takara Bio, Thermo Fisher Scientific.
Analyst Observation – Market Concentration with 10x Genomics Dominance: 10x Genomics leads the single cell multiomics market with an estimated 60-65% share (Chromium platform for droplet-based, Visium for spatial). BD holds ~15% share (Rhapsody platform, CITE-seq). Mission Bio holds ~5% share (Tapestri for DNA+protein). NanoString holds ~5% share (GeoMx DSP for spatial). The market is consolidating around droplet-based multiomics for high-throughput needs and spatial multiomics for tissue context.
For Genomics Research Directors: For large-scale cell atlas projects (10,000+ cells per condition), specify droplet-based multiomics (10x Genomics Chromium Multiome for RNA+ATAC, or CITE-seq for RNA+protein). Budget $10,000-$20,000 per run (consumables), plus compute infrastructure for data analysis (minimum 64 GB RAM, GPU recommended). For spatial multiomics, budget $500-$2,000 per tissue section (NanoString GeoMx, 10x Visium).
For Drug Discovery Executives: For target identification and patient stratification, integrate single cell multiomics early in discovery phase. The additional cost ($50,000-$200,000 per study) is justified by reduced late-stage attrition (better biomarker selection, identification of responder subpopulations). Pharmaceutical companies with established multiomics capabilities report 25-30% higher success rates in Phase II oncology trials.
For Investors: The single cell multiomics market is a high-growth segment (8.5% CAGR) driven by oncology research, immunology, and spatial biology. Key success factors: (1) multi-modality capability (≥2 modalities), (2) high throughput (10,000+ cells per run), (3) FFPE compatibility for clinical samples. Risks: Consumables pricing pressure as competition increases; computational analysis remains bottleneck (lack of standardized pipelines); reimbursement for clinical single cell multiomics is limited (research use only).
Conclusion
The single cell multiomics market is a high-growth, technology-driven segment with projected 8.5% CAGR through 2031. For decision-makers, the strategic imperative is clear: as cancer immunotherapy, neuroscience, and immunology research demand deeper cellular insight, scMulti-omics technologies enabling simultaneous measurement of RNA, protein, chromatin, and spatial context will become standard tools in both academic and pharmaceutical laboratories. The QYResearch report provides the comprehensive data—from segment-level forecasts to competitive benchmarking—required to navigate this $3.58 billion opportunity.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
